Management of Atypical Signet-Ring Cells with Glands in Ascitic Cytology
The finding of atypical signet-ring cells with glandular formation in ascitic fluid mandates urgent diagnostic laparoscopy with direct visualization, peritoneal washings, and targeted biopsies to establish the primary tumor site and extent of peritoneal disease 1.
Immediate Diagnostic Approach
The presence of signet-ring cells in ascitic cytology is highly concerning for malignancy, but cytology alone cannot definitively establish the primary site or guide optimal treatment 2. While signet-ring morphology classically suggests gastric or gastroesophageal junction adenocarcinoma, this finding can arise from multiple primary sites including:
- Gastric/gastroesophageal junction adenocarcinoma (most common)
- Ovarian metastatic disease 3
- Urothelial carcinoma with signet-ring differentiation 4
- Gallbladder carcinoma 5
- Colonic adenocarcinoma 6
Critical Pitfall to Avoid
Do not rely on cytology alone for diagnosis or treatment planning 2. Peritoneal biopsies from cytology specimens are insufficient—they cannot prove the organ of origin or degree of malignancy. The sensitivity of ascitic fluid cytology for detecting peritoneal carcinomatosis is 96.7% when three samples are processed promptly 7, but this only confirms malignant cells are present, not their source.
Recommended Diagnostic Algorithm
Step 1: Diagnostic Laparoscopy (Urgent)
Perform diagnostic laparoscopy with:
- Direct visualization of peritoneal surfaces
- Subphrenic AND pelvic lavage (dual-site lavage significantly enhances sensitivity) 1
- Multiple targeted biopsies of any visible peritoneal nodules
- Systematic inspection for primary tumor site
This is particularly critical given that signet-ring cell histology carries a 46.7% risk of peritoneal metastasis when combined with T3-4 disease and gastric extension >4cm 1.
Step 2: Concurrent Workup During Laparoscopy Planning
While arranging laparoscopy, obtain:
- Upper endoscopy with multiple biopsies (evaluate for gastric/GEJ primary)
- Colonoscopy (evaluate for colonic primary, especially if multifocal strictures present) 6
- CT chest/abdomen/pelvis (assess for primary tumor and metastatic burden)
- Tumor markers:
Step 3: Pathology Review
Ensure expert pathology review with immunohistochemistry to distinguish:
- Gastric/GEJ adenocarcinoma (CK7+/CK20+/CDX2+)
- Urothelial origin (CK7+/CK20+/GATA3+/uroplakin+) 4
- Ovarian metastatic disease (CK7+/PAX8+)
- Colonic origin (CK20+/CDX2+/CK7-)
Treatment Direction Based on Primary Site
If Gastroesophageal Junction/Gastric Primary Confirmed:
Perioperative chemotherapy is the preferred approach 1. The FLOT regimen (docetaxel, oxaliplatin, leucovorin, fluorouracil) has demonstrated superior survival compared to older regimens and is the standard for locally advanced resectable gastric/GEJ adenocarcinoma 1.
Key consideration: The presence of signet-ring cells with peritoneal involvement typically indicates stage IV disease. If peritoneal carcinomatosis is confirmed at laparoscopy, the patient is not a surgical candidate and should proceed directly to systemic chemotherapy.
If Other Primary Site Identified:
- Ovarian primary with peritoneal carcinomatosis: Treat per ovarian cancer guidelines with cytoreductive surgery and platinum-based chemotherapy 8
- Urothelial carcinoma: Platinum-based chemotherapy (cisplatin/gemcitabine or carboplatin/gemcitabine) 4
- Colonic primary: FOLFOX or FOLFIRI-based regimens
Critical Clinical Context
Signet-ring cell histology portends aggressive biology and high risk of peritoneal spread 1. The predicted risk of peritoneal metastases increases from 7.5% at 2cm beyond the GEJ to 35% at 4cm or beyond when signet-ring components are present 1. This aggressive behavior necessitates rapid diagnostic workup—delays in establishing the primary site and initiating appropriate therapy directly impact mortality.
Do not initiate empiric chemotherapy without tissue diagnosis from laparoscopy 9. While neoadjuvant chemotherapy may be considered for bulky disease, pathologic confirmation through biopsy (not just cytology) is mandatory before starting systemic therapy 9.
The finding of atypical signet-ring cells represents a diagnostic emergency requiring coordinated multidisciplinary evaluation within days, not weeks, given the rapid progression potential of these tumors 5, 6.